[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1106927T1 - Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης - Google Patents

Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης

Info

Publication number
CY1106927T1
CY1106927T1 CY20071101307T CY071101307T CY1106927T1 CY 1106927 T1 CY1106927 T1 CY 1106927T1 CY 20071101307 T CY20071101307 T CY 20071101307T CY 071101307 T CY071101307 T CY 071101307T CY 1106927 T1 CY1106927 T1 CY 1106927T1
Authority
CY
Cyprus
Prior art keywords
pde3
pde4
histamin
competitor
inhibitor
Prior art date
Application number
CY20071101307T
Other languages
English (en)
Inventor
Rolf Beume
Daniela Bundschuh
Christian Weimar
Stefan-Lutz Wollin
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of CY1106927T1 publication Critical patent/CY1106927T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά την συνδυασμένη χορήγηση των PDE4 ή PDE3/4 αναστολέων και ανταγωνιστών υποδοχέα ισταμίνης για την θεραπευτική αγωγή αναπνευστικών ασθενειών.
CY20071101307T 2002-03-06 2007-10-11 Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης CY1106927T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02004987 2002-03-06
EP03708130A EP1482938B1 (en) 2002-03-06 2003-02-25 Pharmaceutical composition of a pde4 or a pde3/4 inhibitor and a histamine receptor antagonist

Publications (1)

Publication Number Publication Date
CY1106927T1 true CY1106927T1 (el) 2012-09-26

Family

ID=27771841

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20071101307T CY1106927T1 (el) 2002-03-06 2007-10-11 Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
CY20131100163T CY1113894T1 (el) 2002-03-06 2013-02-21 Φαρμακευτικη συνθεση που περιλαμβανει ροφλουμιλαστη και λεβοκετιριζινη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20131100163T CY1113894T1 (el) 2002-03-06 2013-02-21 Φαρμακευτικη συνθεση που περιλαμβανει ροφλουμιλαστη και λεβοκετιριζινη

Country Status (32)

Country Link
US (1) US20050112069A1 (el)
EP (2) EP1482938B1 (el)
JP (1) JP5150034B2 (el)
KR (1) KR20040095255A (el)
CN (1) CN101257904A (el)
AR (1) AR038858A1 (el)
AT (1) ATE369134T1 (el)
AU (1) AU2003212268B2 (el)
BR (1) BR0308220A (el)
CA (1) CA2478612C (el)
CO (1) CO5611148A2 (el)
CY (2) CY1106927T1 (el)
DE (1) DE60315426T2 (el)
DK (2) DK1849468T3 (el)
EA (2) EA007903B1 (el)
ES (2) ES2291618T3 (el)
HK (1) HK1071308A1 (el)
HR (1) HRP20040909B1 (el)
IL (1) IL163336A (el)
IS (2) IS2536B (el)
MX (1) MXPA04008460A (el)
NO (1) NO335254B1 (el)
NZ (1) NZ535611A (el)
PL (1) PL211574B1 (el)
PT (2) PT1849468E (el)
RS (1) RS51018B (el)
SG (1) SG160197A1 (el)
SI (2) SI1482938T1 (el)
TW (1) TWI347845B (el)
UA (1) UA80117C2 (el)
WO (1) WO2003074055A1 (el)
ZA (1) ZA200407104B (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101355876B (zh) * 2005-11-09 2012-09-05 康宾纳特克斯公司 一种适用于眼部给药的组合物
WO2008074803A2 (en) * 2006-12-20 2008-06-26 Glaxo Group Limited 4-benzyl-l ( 2h) -phthalazinones as h1 receptor antagonists
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
RU2009141592A (ru) * 2007-04-11 2011-05-20 Алькон Рисерч, Лтд. (Us) ПРИМЕНЕНИЕ ИНГИБИТОРА TNFα В СОЧЕТАНИИ С АНТИГИСТАМИННЫМ СРЕДСТВОМ ДЛЯ ЛЕЧЕНИЯ АЛЛЕРГИЧЕСКОГО РИНИТА И АЛЛЕРГИЧЕСКОГО КОНЪЮНКТИВИТА
US8877816B2 (en) 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
KR20090061972A (ko) * 2007-12-12 2009-06-17 한미약품 주식회사 베포타스틴 p-톨루엔술폰산염의 결정형, 이의 제조방법 및이를 포함하는 약학 조성물
CA2826183C (en) 2011-02-07 2019-05-14 Scipharm Sarl Novel composition for the treatment of cystic fibrosis
KR102226833B1 (ko) * 2013-06-28 2021-03-12 한미약품 주식회사 레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
CA2993462A1 (en) * 2014-08-26 2016-03-03 Fundacion Para La Investigacion Medica Aplicada Products for the treatment and prevention of neurological disorders coursing with a cognition deficit or impairment, and of neurodegenerative diseases
WO2016054971A1 (zh) 2014-10-09 2016-04-14 南京明德新药研发股份有限公司 羟基嘌呤类化合物及其应用
CN109956947A (zh) * 2017-12-25 2019-07-02 江苏恒瑞医药股份有限公司 一种cns抑制剂的新晶型、制备方法及用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2847693A1 (de) * 1978-11-03 1980-05-22 Hoechst Ag Verfahren zur herstellung von pyrimido-(6,1-a)-isochinolin-2-onen
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
ES2176252T3 (es) * 1993-07-02 2002-12-01 Altana Pharma Ag Benzamidas sustituidas con fluoro-alcoxi y su utilizacion como agentes inhibidores de fosfodiesterasas de nucleotidos ciclicos.
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5990147A (en) * 1997-11-07 1999-11-23 Schering Corporation H3 receptor ligands of the phenyl-alkyl-imidazoles type
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
EP1244654A1 (en) * 1999-10-25 2002-10-02 ALTANA Pharma AG Tetrahydrothiopy ranphthalazinone derivatives as pde4 inhibitors
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
GB0115181D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
EP1849468A3 (en) 2007-11-07
JP2005524666A (ja) 2005-08-18
SI1482938T1 (sl) 2007-12-31
ES2291618T3 (es) 2008-03-01
EP1849468A2 (en) 2007-10-31
SG160197A1 (en) 2010-04-29
HRP20040909B1 (en) 2012-11-30
EA200401137A1 (ru) 2005-04-28
AU2003212268B2 (en) 2008-09-11
CN101257904A (zh) 2008-09-03
HRP20040909A2 (en) 2005-08-31
IS7438A (is) 2004-09-03
PL371056A1 (en) 2005-06-13
TW200306855A (en) 2003-12-01
CA2478612C (en) 2013-12-10
DK1849468T3 (da) 2013-02-04
IS2536B (is) 2009-08-15
JP5150034B2 (ja) 2013-02-20
AU2003212268A1 (en) 2003-09-16
ATE369134T1 (de) 2007-08-15
EP1849468B1 (en) 2012-12-05
ES2400670T3 (es) 2013-04-11
NZ535611A (en) 2006-03-31
CY1113894T1 (el) 2016-07-27
ZA200407104B (en) 2006-12-27
PT1849468E (pt) 2013-02-27
NO20044230L (no) 2004-12-06
EA007903B1 (ru) 2007-02-27
RS51018B (sr) 2010-10-31
US20050112069A1 (en) 2005-05-26
CA2478612A1 (en) 2003-09-12
UA80117C2 (uk) 2007-08-27
PL211574B1 (pl) 2012-05-31
IL163336A (en) 2009-02-11
BR0308220A (pt) 2005-01-04
MXPA04008460A (es) 2004-12-06
EP1482938A1 (en) 2004-12-08
DK1482938T3 (da) 2007-12-03
EA010886B1 (ru) 2008-12-30
PT1482938E (pt) 2007-11-15
RS78004A (en) 2006-12-15
WO2003074055A1 (en) 2003-09-12
EA200601592A1 (ru) 2006-12-29
KR20040095255A (ko) 2004-11-12
TWI347845B (en) 2011-09-01
SI1849468T1 (sl) 2013-03-29
NO335254B1 (no) 2014-10-27
CO5611148A2 (es) 2006-02-28
EP1482938B1 (en) 2007-08-08
HK1071308A1 (en) 2005-07-15
IS8760A (is) 2008-09-04
DE60315426T2 (de) 2008-07-03
AR038858A1 (es) 2005-01-26
DE60315426D1 (de) 2007-09-20

Similar Documents

Publication Publication Date Title
CY1106927T1 (el) Φαρμακευτικη συνθεση ενος pde4 ή pde3/4 αναστολεα και ανταγωνιστη υποδοχεα ισταμινης
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
DE60234616D1 (de) Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
BR0308243A (pt) Composto, formulação farmacêutica, e, métodos de tratar diabetes, doença de alzheimer, e de inibir gsk-3 em um mamìfero
CY1109860T1 (el) Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
CY1104993T1 (el) 4-(πιπεριδυλ- και πυρρολιδινυλ-αλκυλ-ουρεϊδο)-κινολινες ως ανταγωνιστες του υποδοχεα ουροτασινης ii
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1114803T1 (el) Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
WO2005072308A3 (en) Cgrp receptor antagonists
SE0101932D0 (sv) Pharmaceutical combinations
SE0302488D0 (sv) New combination
NO20043115L (no) Substituerte diketopiperaziner som oksytocin antagonister
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
DK1497292T3 (da) Azaindolylpiperidinderivater som antihistamin- og antiallergimidler
ATE325115T1 (de) Pyrimidinderivate als selektive cox-2-inhibitoren
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
NO20033634L (no) GLyT-1-inhibitorer
EA200401617A1 (ru) Комбинация nmda-антагониста и ингибиторов ацетилхолинэстеразы для лечения болезни альцгеймера
ITMI20022594A1 (it) Combinazione terapeutica per la cura dell'ipertensione.